Technology
2024 SABCS|Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
YANTAI, China, Dec. 13, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331
By: prnewswire_apac
- Dec 13 2024
- 0
- 0 Views
Share this page
Guest Posts by Easy Branches
